http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이상훈,박성준,최철,안진우,김철우,Lee, Sang-Hun,Park, Sung-Jun,Choi, Cheol,Ahn, Jin-Woo,Kim, Cheul-U 전력전자학회 2003 전력전자학회 논문지 Vol.8 No.1
In SRM driving, the current rate is directly related to the rate of switching device and in cost reduction, the Parallel switching operation is the alternatives because it has the smaller current rate through current division. There ire many investigations for the parallel switching operations to equaling the current division. However it remains many problems for practical usage. The reason Is that the switching characteristics are mainly relied on the different saturation voltage of each device etc. and these factors are not altered by a circuit designer. In order to compensate this problem, a proper resistance is experimently inserted to the switching device. But this method can not be the optimal solution. Therefore this paper propose a new parallel operation of SRM which uses a parallel phase winding to remove the traditional effect of switching device such as saturation voltage according to the division of current. Also the reliable and stable driving is improved through experiments and the detailed principles. SRM의 구동에 있어 전류정격은 스위칭 소자의 정격과 직결되고 경제적인 측면에서 적은 정격전류 스위칭 소자를 이용하여 구동하기 위해서는 스위칭 소자의 병력운전이 필수적이다. 스위칭 소자의 병렬 운전시 스위칭 소자의 전류분담을 균일하기 위해서 제조업체의 기술자료를 중심으로 많은 연구가 이루어졌으나, 아직도 실용화하기 위해서는 많은 문제를 앉고 있다. 스위칭 소자의 병력운전은 스위치의 특성 즉, 전류에 대한 상이한 포화전압이 그 근본적인 원인이 되고 있다. 이를 보상하기 위해서 스위칭 소자에 직렬로 적당한 저항값을 삽입하는 방법이 있지만 이 방법은 근본적인 대책이 될 수 없다. 본 논문에서는 스위칭 소자의 포화전압과 같은 파라메터가 전류분담에 영향을 미치지 않는 새로운 병렬운전기법인 상권선 병력운전기법 제안하였다.
김상욱(Sang Wook Kim),송태호(Tae Ho Song),김철우(Cheul Woo Kim),권기익(Ki Ik Kwon),유언호(Un Ho Ryoo) 대한내과학회 1994 대한내과학회지 Vol.47 No.1
Background: Hypertension is a major risk factor for atherosclerotic vascular disease. Many antihypertensive drugs are known to alter lipoprotein metabolism and this may override the benefit of blood pressure reduction. The purpose of this study is to evaluate the effects of the antihypertensive therapy in serum lipid. Method: The clinical study was done on 200 patients with hypertension who treated with esidrex, beta-blocker, or esidrex plus beta-blocker as an antihypertensive medication. The patients were divided into three groups according to the antihypertensive regimens. The serum lipid values were checked before and during antihypertensive therapy. Average follow up period of serum lipid was about 2 years. Results : 1) The serum lipid values before antihypertensive therapy were triglyceride 177±125 mg/dl, HDL-cholesterol 42±12 mg/dl, total cholesterol 230±50 mg/dl, and 1 year after antihypertensive therapy, triglyceride 233±134 mg/dl, HDL-cholesterol 43±22 mg/dl, total cholesterol 235±47 mg/dl, and 2 year after antihypertensive therapy, triglyceride 243±172 mg/dl, HDL-cholesterol 45±11 mg/dl, total cholesterol 233±40 mg/dl. The serum triglyceride and total cholesterol were increased significantly after antihypertensive therapy. 2) In 30 patients with esidrex therapy, the serum total cholesterol was elevated than the pretreatment value (p<0.05); pretreatment value 228±59 mg/dl, 6 months 233±53 mg/dl, 1 year 239±53 mg/dl, 2 year 238±39 mg/ dl. 3) In 81 patients with beta-blocker therapy, the serum triglyceride was elevated than the pretreatment value (p<0.05); pretreatment value 164±67 mg/dl, 6 months 183±72 mg/dl, 1 year 245±75 mg/dl, 2 year 205±84 mg/ dl. 4) In 89 patients with esidrex plus beta-blocker therapy, the serum total cholesterol was elevated than pretreatment value (p<0.05); pretreatment value 210±45 mg/dl, 6 month 264±50 mg/dl, l year 237±53 mg/dl, 2 year 225±48 mg/di, and triglyceride was also elevated; pretreatment value 163±87 mg/dl, 6 months 195±76 mg/dl, 1 year 208±80 mg/dl, 2 year 211±85 mg/ dl, But the serum HDL cholesterol was not elevated significantly. Conclusion : The esidrex therapy was associated with the elevation of serum total cholesterol and beta- blocker therapy was associated with the elevation of serum triglyceride. The serum total cholesterol and triglyceride were increased during esidrex plus beta-blocker therapy.
강유정(Yu-Jung Kang),안진우(Jin-Woo Ann),박성준(Sung-Jun Park),김철우(Cheul-U Kim) 전력전자학회 2001 전력전자학술대회 논문집 Vol.2001 No.7
SRM(Switched Reluctance Motor) uses reluctance torque by pulse excitation control. SRM drives are much studied in electrical vehicles and industrial application due to the simple, robust mechanical structure and high speed characteristics. For the high performance control of SRM, it is necessary to synchronize the stator phase excitation with the rotor position.<br/> This paper proposes a new encoder for high performance excitation control of SRM The proposed encoder has complex structures of incremental and absolute encoder. An each phase inductance profile can be synchronized with 4-bit absolute position signal and incremental pulses are used for speed detection. Low cost and simple manufacturing of SRM encoder is possible.